SLAMF7 and B-cell chronic lymphocytic leukemia: SLAMF7/CD319, along with SLAMF1/CD150, was shown to affect the degranulation capacity of primary NK cells from CLL patients and have an antagonistic effect on the BCR pathway via recruitment of prohibitin-2 (PHB2) [38].